Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (68)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Casadevall, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casadevall, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 42-47
© 2002 European Renal Association-European Dialysis and Transplant Association


Antibodies against rHuEPO: native and recombinant

Nicole Casadevall

Service d'Hématologie Biologique, Hôtel-Dieu, Paris, France

Abstract

Recombinant human erythropoietin (rHuEPO) has been used successfully to correct the anaemia of chronic renal failure for more than 12 years. During this time, neutralizing anti-erythropoietin antibodies have been reported in only three patients. However, during the last 2 years, 21 rHuEPO-treated patients have been referred to our laboratory because of sudden resistance to the recombinant hormone and a pure red cell aplasia requiring red blood cell transfusion. The clinical pattern presented by these patients suggested that they could have developed neutralizing anti-erythropoietin antibodies. In all cases, there was evidence of the presence of strong neutralizing antibodies. The ability of the patient's sera to neutralize erythropoietin and to inhibit erythroid colony formation from normal bone marrow was tested first. The presence of anti-erythropoietin antibodies was then demonstrated directly by immunoprecipitation of radiolabelled erythropoietin using native, deglycosylated, and denaturated erythropoietin. The reasons for anti-erythropoietin antibody production in these patients is unclear, although it is clearly related to the treatment with rHuEPO. A plausible explanation would be a slight modification in the production process leading to some antigenicity of the manufactured hormone. However, this hypothesis remains unproven. Prompt detection of such antibodies appears necessary to limit antibody titre and to speed recovery. Immunosuppressive treatment was followed by disappearance of the antibodies in 16 of the cases.

Keywords: anaemia; anti-erythropoietin antibodies; chronic kidney disease; pure red cell aplasia

Notes

Correspondence and offprint requests to: Professor Nicole Casadevall, Hôpital Hotel Dieu, 1, place Parvis Notre-Dame, F-75004 Paris, France. Email: nicole.casadevall{at}htd.ap\|[hyphen]\|hop\|[hyphen]\|paris.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.